搜索
TriSalus Life Sciences Inc
TLSI添加自选
2.680USD
+0.160+6.35%
收盘 05/15, 16:00（美东）报价延迟15分钟
164.60M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.35%
5天
-39.50%
1月
-40.31%
6月
-41.23%
今年开始到现在
-61.60%
1年
-47.86%
TradingKey TriSalus Life Sciences Inc股票评分
单位: USD 更新时间: 2026-05-15操作建议
TriSalus Life Sciences Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名106/382位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.20。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
TriSalus Life Sciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
TriSalus Life Sciences Inc亮点
亮点风险
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
业绩高增长
公司营业收入稳步增长，连续3年增长143.91%
业绩增长期
公司处于发展阶段，最新年度总收入45.15M美元
估值合理
公司最新PE估值-1.89，处于3年历史合理位
机构加仓
最新机构持股14.73M股，环比增加17.64%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值3.46K
活跃度增加
近期活跃度增加，过去20天平均换手率3.19
分析师目标
根据
5
位分析师
买入
评级
9.200
目标均价
+265.08%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TriSalus Life Sciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TriSalus Life Sciences Inc简介
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
公司代码TLSI
公司TriSalus Life Sciences Inc
CEOSzela (Mary T)
网址https://trisaluslifesci.com/
相关品种
